Krishnan Krish S 4

What Happened Krishnan Krish, a 10% owner of Krystal Biotech (KRYS), sold 25,000 shares on March 4, 2026 in multiple open-market trades (reported March 6, 2026). Total proceeds were approximately $6,579,164. Individual blocks included: 483 sh @ $257.31 ($124,282); 470 @ $258.38 ($121,438); 1,377 @ $259.87 ($357,838); 3,128 @ $260.49 ($814,802); 2,962 @ $261.41 ($774,289); 2,380 @ $262.44 ($624,619); 2,043 @ $263.70 ($538,741); 8,798 @ $264.85 ($2,330,151); 2,439 @ $265.59 ($647,773); and 920 @ $266.56 ($245,231). Overall prices were roughly in the $257–$266.6 range. These were sales (S), which are generally routine dispositions rather than a purchase/bullish signal.

Key Details

• Transaction date: March 4, 2026; Form 4 filed March 6, 2026 (appears timely — filed within typical two business days).
• Total sold: 25,000 shares for ~ $6.58 million.
• Price details: reported as weighted averages for multiple-trade batches; reported per-block prices and underlying ranges are documented in footnotes (approx ranges from ~$256.81 up to ~$266.93 across trades).
• Plan: Sales were made pursuant to a Rule 10b5-1 trading plan adopted Sept 4, 2025 (effective Dec 4, 2025 through Dec 4, 2026) — indicates pre-planned trades.
• Ownership reporting: Krish may be deemed to beneficially own shares held by his spouse and the Krishnan Family Trust; those holdings/transactions are reported separately by his spouse/trust on other Form 4s. This filing does not disclose "shares owned after the transaction."
• Transaction code: S = Sale.

Context

• Rule 10b5-1 plans allow insiders to sell shares at pre-set times to avoid trading on nonpublic information; disclosures note these trades followed such a plan.
• As a 10% owner, Krish is a significant insider; sales by large holders can be for many reasons (portfolio management, diversification, tax planning) — the filing itself gives no motive.
• No derivatives, option exercises, gifts, or tax-withholding transactions are reported in this filing.